Colonial Trust Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$111K Sell
224
-13
-5% -$5.76K 0.01% 266
2026
Q1
$106K Buy
237
+64
+37% +$29.8K 0.01% 266
2025
Q4
$78.4K Sell
173
-50
-22% -$21.6K 0.01% 297
2025
Q3
$87.3K Buy
223
+13
+6% +$5.43K 0.01% 276
2025
Q2
$93.5K Hold
210
0.01% 266
2025
Q1
$102K Buy
210
+50
+31% +$23.3K 0.01% 258
2024
Q4
$64.4K Hold
160
0.01% 285
2024
Q3
$74.4K Sell
160
-100
-38% -$48K 0.01% 291
2024
Q2
$122K Sell
260
-19
-7% -$8.25K 0.01% 229
2024
Q1
$117K Buy
279
+3
+1% +$1.27K 0.01% 230
2023
Q4
$112K Buy
276
+245
+790% +$90.5K 0.01% 227
2023
Q3
$10.8K Hold
31
﹤0.01% 505
2023
Q2
$10.9K Buy
31
+15
+94% +$5.05K ﹤0.01% 513
2023
Q1
$5.04K Sell
16
-5
-24% -$1.5K ﹤0.01% 618
2022
Q4
$6.06K Buy
+21
New +$6.4K ﹤0.01% 589

Other funds holding VRTX

Colonial Trust Advisors's VRTX Position: Q2 2026 in Review

Colonial Trust Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.5% in Q2 2026, selling an estimated $5.76K and leaving 224 shares worth $111K. The position accounts for 0.01% of the portfolio, ranked #266.

Colonial Trust Advisors first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $122K in Q2 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Colonial Trust Advisors held 224 shares of Vertex Pharmaceuticals worth $111K as of Q2 2026.
  • Colonial Trust Advisors sold 13 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.76K.
  • Vertex Pharmaceuticals made up 0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #266 holding.
  • Colonial Trust Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Colonial Trust Advisors's Vertex Pharmaceuticals position peaked at $122K in Q2 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.